Beyond insulin therapy: Comparing relative benefits of adding SGLT2 versus DPP4 inhibitors in poorly controlled type 2 diabetic patients: A systematic review and meta-analysis.
Direct comparison shows which newer drug works better when added to insulin for difficult-to-control diabetes, filling a critical gap in treatment guidance.
This systematic review and meta-analysis directly compares SGLT2 inhibitors versus DPP4 inhibitors as add-on therapy to insulin in poorly controlled type 2 diabetes, an extremely common clinical management decision. The comparative evidence synthesis fills a gap in direct comparison data.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- Poorly controlled type 2 diabetes patients on insulin therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Primary Care Diabetes
Why it surfaced
Meta-analysis addressing common clinical decision point; SGLT2i watchlist match; lower-impact journal limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.